YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Energy & Financials Lead S&P 500/Markets On Monday! – $AAPL $CVX $GOOG $SHIP $TSLA Rise

By John F. Heerdink, Jr.
“It takes a long time to grow an old friend.” – John Leonard, Australian Poet, Born: July 7, 1965


Happy Monday!

8 of the 11 sectors closed in the green today as the S&P 500 closed at 4,468.73 (+.23%), the Dow 30 closed at 34,869.63 (+.76%), but the Nasdaq closed lower at 15,248.25 (-.25%). The energy sector led all with an impressive 2.9% gain as oil prices closed at $70.47/bbl up 1% on the day, while the financials also rose 1.1%. Energy giant Chevron (CVX) closed at $97.97, +1.98% after announcing that Chevron U.S.A. Inc., through its Chevron New Energies division, and a subsidiary of Enterprise Products Partners L.P. (NYSE: EPD) announced a framework to study and evaluate opportunities for carbon dioxide (CO2) capture, utilization, and storage (CCUS) from their respective business operations in the U.S. Midcontinent and Gulf Coast. The companies expect the initial phase of the study in which they will evaluate specific business opportunities to last about six months. leading the 3 sectors that closed in the red was the health care sector, which dropped .6% as some ‘experts’ were reported by The Lancet to be calling in the question the need for a COVID-19 booster shot, thus muddying the waters once again. 

The small caps on the Russell 2000 also landed in positive territory closing at 2,240.78 (+.59%). In contrast, the MicroCaps moved lower again today as the iShares Micro-Cap ETF (IWC) closed at $146.14, (-.1%), but did manage to closie near the high of the day at of $146.95.

The macroeconomic schedule was limited the Treasury Budget report for August, which confirmed a $170.64B deficit in August, while the fiscal YTD budget deficit is $2.71T. Tomorrow’s schedule will deliver the Consumer Price Index report for August & the NFIB Small Business Optimism Survey for August. 

The yield curve tightened again today, as the 10-yr treasury yield closed down 2 basis points at 1.32%, while the 2-yr yield stayed pat at .21%. The U.S. Dollar Index moved up by .1% to close at 92.64.

The precious metals markets ended with gold prices closing at $1,795, +$5 and silver closed at $23.77, -$.01.

BIOTECH BUT CYTOVIA RAISES & INM’s DEFINITIVE AGREEMENT

 The SPDR S&P Biotech ETF (XBI) closed at $131.08, -.49%, the iShares Nasdaq Biotechnology ETF (IBB) closed at $170.32, -1.68% & the NYSE ARCA Biotech Index (^BTK) closed at 5,840.03, -.71%.

One our portfolio companies in the biotech sector, privately owned Cytovia Therapeutics, Inc. , a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited iNK and CAR (Chimeric Antigen Receptor)-iNK cells derived from induced pluripotent stem cells (iPSCs) and NK cell engager multifunctional antibodies, and CytoLynx Therapeutics (“CytoLynx), its newly-formed China-focused joint venture, announced today that they have closed $45 million from institutional investors to finance the IND enabling and initial clinical development of their pipeline. Cytovia’s management is currently targeting to go public in early 2022. 

Cytovia and TF Capital, a leading China-based biotech institutional investor, have formed CytoLynx Therapeutics. TF Capital along with YF Capital, BioTrack Capital, Ruihua Capital, and TG Sino-Dragon Fund (backed by TigerMed) have invested $45 million to support the new venture, as well as Cytovia research and development projects. The collaboration agreements between CytoLynx and Cytovia will advance multiple NK therapeutics through product development in the Greater China region. Additionally, CytoLynx obtained a technology license from Cytovia based on its core technologies to allow in-China development of additional NK therapeutics for global commercialization. Cytovia is eligible to receive up to $400 million in upfront development and commercial milestones under the agreement.

Dr. Daniel Teper, Chairman and CEO of Cytovia commented: “We are excited to accelerate the global development of our lead GPC3 programs for the treatment of hepatocellular carcinoma, a condition with significant unmet medical needs and a very large patient population in Asia, particularly in China, and establish a path to provide these therapies to the Chinese market. CytoLynx will also serve as a development and commercialization platform for additional Cytovia products, as well as in-licensed immuno-oncology assets.” Learn more by reviewing their September 2021 presentation.

InMed Pharmaceuticals (INM) announced today that it has entered into a definitive agreement to acquire BayMedica Inc., a private company based in the US that specializes in the manufacturing and commercialization of rare cannabinoids. The Definitive Agreement follows a previously signed letter of intent announced on June 29, 2021. The transaction, which is subject to certain standard closing conditions, is expected to close in the coming weeks. Upon closing, InMed will become a global leader in the manufacturing of rare cannabinoids, with expertise in three distinct and complementary cannabinoid manufacturing approaches. InMed’s proprietary cannabinoid manufacturing process, IntegraSyn™, combined with BayMedica’s synthetic biology and chemical synthesis capabilities, will provide InMed with complete manufacturing flexibility to select the most appropriate, cost-effective method based on the target cannabinoid and appropriate quality specifications for the desired market segment. In parallel to cannabinoid manufacturing, the combined company will continue to explore the therapeutic potential of cannabinoids and novel cannabinoid analogs for pharmaceutical drug development, as well as expand commercial sales of rare cannabinoids to the consumer health and wellness sector. Revenues of BayMedica’s initial rare cannabinoid product, Prodiol® CBC (cannabichromene), have grown steadily since sales commenced in December 2019, with cumulative revenues in excess of US$2.5M. BayMedica leads the industry in large batch production of CBC with current batch sizes of more than 200kg and an ability to increase to metric ton quantities as market demand increases. BayMedica is focused on the wholesale to consumer health and wellness markets, including nutraceuticals, cosmetic, functional food and beverage, as well as animal health markets. In addition to CBC, BayMedica has several high value non-intoxicating rare cannabinoids in various stages of commercial manufacturing scale-up including CBDV, THCV, CBGV, CBT and CBN for the health and wellness markets.

TECH MOVES 

 A few tech giants closed as follows: Alphabet (GOOG) which closed at 2,869.30, +1.09, Facebook (FB) closed at $376.51, -.58%, Amazon (AMZN) closed at $3,457.17, -.35%, Microsoft (MSFT) closed at $296.99, +.43%, Apple (AAPL, $149.55, +.39%),  Netflix (NFLX, $589.29, -1.58%) & Tesla (TSLA, $743, +.91%).

MEMES WATCH

AMC Entertainment (AMC) stays d strong and closed at $51.69, +3.05%.

GameStop (GME) had a very nice day as it closed at $203.40, 6.82%. GME released their financial results for the second quarter ended July 31, 2021 last week. They generated their net sales of $1.183 billion, compared to $942 million in the prior year’s second quarter & ended the period with cash and restricted cash of $1.78 billion, ended the period with no long-term debt, other than a $47.5 million low-interest loan associated with the French government’s pandemic response & invested in long-term growth initiatives that include expanding the Company’s product catalog, enhancing its fulfillment network capabilities and technology, and adding talent across the organization.

Virgin Galactic Holdings (SPCE) continued to languish and closed at $24.26, -3.58%. 

Shares of infamous ‘meme brokerage’ firm Robinhood Markets, Inc., (HOOD) closed at $40.60, -1.38%. 

Shares of Seanergy Maritime Holdings Corp. (SHIP) moved up strongly today as it closed at $1.40, +12% after reaching $1.44 in tardy trading.  SHIP, the only pure-play Capesize ship-owner publicly listed in the US, announced last week that it took delivery of the previously-announced Capesize vessel acquisition, the M/V Worldship (the “Vessel”). The Vessel is a 181,415 dwt Capesize bulk carrier, built in 2012 by Imabari of Japan. The M/V Worldship is the sixth Capesize delivery that Seanergy has successfully completed in 2021 to-date. M/V Worldship has already entered a time charter (“T/C”) with an existing charterer of the Company, at a gross fixed rate of $31,750 per day for a period of about 12 to about 16 months from the delivery. SHIP recently announced that its Board of Directors has authorized a share repurchase plan. Under the Plan, the Company may repurchase up to $17 million of its outstanding common shares, representing approximately 10% of the Company’s market capitalization as of August 10, 2021. 

VP WATCHLIST HIGHLIGHTS

Our complete VP Watchlist is a list that we believe deserves consideration for short term and long term portfolio adds that include Apple, Tesla, Disney & 8 other names currently. The dedicated pages for each of these companies will enable you to stay informed and learn more about these companies daily. Please review few of the updates on a few of the VP Watchlist companies below:


  • Shares of VP Watchlist stock, INmune Bio (NASDAQ: INMB) closed trading at $21.39, -.83% after reaching $23.33 in intraday trading. 
    • On Wednesday, Aug. 4th, INmune Bio, Inc. reported its financial results for the second quarter ended June 30, 2021 and provided a business update. Raymond J Tesi, M.D., CEO/CMO of INmuneBio (INMB) stated, “We continue our planning and setup for a Phase 2 clinical trial of our lead candidate, XPRO™ (Xpro1595™), in patients with mild Alzheimer’s disease, which we plan to initiate by year-end. We have already demonstrated that XPRO™ can reduce neuroinflammation and decreases biomarkers of neurodegeneration and improve synaptic function. If successful in Phase 2, we believe XPRO™ has the potential to be among the most significant advancements in the treatment of Alzheimer’s Disease (AD) and other neurodegenerative diseases in many years. At the Alzheimer’s Association International Conference last week, we introduced a new biomarker – Apparent Fiber Density (AFD), a measure of axonal integrity measured by MRI. XPRO™ increases AFD in patients receiving 1mg/kg/week. We believe the novel non-invasive white matter analytics of white matter free water and apparent fiber density will be very useful in the development of XPRO™ in AD, Treatment Resistant Depression (TRD) and the many other CNS indications we hope to attack in the future. Last month, we treated the first patient in the first Phase 1 clinical trial of our NK cell priming platform, INKmune, in high-risk myelodysplastic syndrome (MDS). We are calling INKmune a pseudokine because, in vitro, it converts the resting NK cells into memory-like NK cells that can kill cancer cells as well or better than NK cells treated cytokines such as IL-12, IL-15 and IL-18 alone or in combination.”
    • On July 26th, INmune Bio announced the design of its upcoming Phase 2 clinical trial of XProTM in patients diagnosed with mild Alzheimer’s disease (AD) at AAIC. The announcement was accompanied by the release of additional biomarker data from the Phase 1b AD trial that shows improvement in white matter (myelinated axons) that degenerate in AD patients. READ MORE. 
 

  • Shares of Fate Therapeutics (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, closed at $65.78/share, -3.87%. The 52-wk high is $121.16. 
    •  On August 19th, FATE highlighted positive interim clinical data from the Company’s FT516 and FT596 programs for patients with relapsed / refractory B-cell lymphoma. FT516 is the Company’s universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with a novel high-affinity, non-cleavable CD16 (hnCD16) Fc receptor, which is designed to maximize antibody-dependent cellular cytotoxicity (ADCC), a potent anti-tumor mechanism by which NK cells recognize, bind and kill antibody-coated cancer cells. The Company’s FT596 program incorporates both the hnCD16 Fc receptor and a chimeric antigen receptor (CAR) targeting CD19, which is designed to enable multi-antigen targeting of tumor cells, as well as an IL-15 receptor fusion (IL-15RF) to enhance NK cell activity and survival.
    • On August 4th, Fate reported business highlights and financial results for the second quarter ended June 30, 2021. Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics stated, “We are very pleased with the early clinical safety and activity we have observed with our off-the-shelf, iPSC-derived NK cell programs in relapsed / refractory lymphoma and acute myeloid leukemia, where interim Phase 1 data indicate FT516 and FT538 are well tolerated and can deliver complete responses for patients. We look forward to sharing additional clinical data from our FT516 and FT596 programs in B-cell lymphoma at our upcoming investor event. Additionally, treatment of the first patient with FT819, the first-ever iPSC-derived T-cell therapy to undergo clinical investigation, is a landmark achievement and further demonstrates the Company’s leadership in off-the-shelf, iPSC-derived cell therapy and the versatility of its proprietary iPSC Product Platform.”
    • On Aug. 2 Fate announced that the first patient has been treated with FT819, an off-the-shelf chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies. FT819 is the first-ever CAR T-cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line, a renewable cell source that enables mass production of high quality, allogeneic CAR T cells with greater product consistency, off-the-shelf availability, and broader patient accessibility. FT819 is engineered with several first-of-kind features designed to improve the safety and efficacy of CAR T-cell therapy.



  • INVO Bioscience (NASDAQ: INVO) is a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System. Shares of INVO closed at $3.58.
    • On September 9th, INVO Bioscience announced that it has completed the acquisition of a Canadian-based entity that was originally formed to offer INVOcell in Canada. The entity had previously completed a number of important procedures and documentation necessary to establish INVOcell within clinical operations in Canada. INVO Bioscience anticipates leveraging this entity to advance the distribution of INVOcell, and take advantage of the existing product registration which approved the device for sale based on 5-day incubation in the Canadian market. In addition, the Company is initiating the development of joint ventures to establish INVO Centers within the Canadian marketplace, similar to U.S. and Mexico markets, to further drive accelerated adoption of the INVOcell solution while also increasing much needed capacity and patient access within the fertility industry. Steve Shum, CEO of INVO Bioscience, commented, “We believe Canada offers an excellent opportunity to further expand our distribution efforts of INVOcell while also advancing our joint-venture based INVO Center model. With roughly 16% (or 1 in 6) couples in Canada experiencing infertility, a number that has doubled since the 1980s, and with a popultion of 37.74 million, Canada represents a sizable market opportunity. Canada also faces similar issues that hamper other parts of the world, including a large underserved population, access/capacity constraints and affordability challenges. We appreciate the key individuals in Canada that originally created this entity to help promote and bring our INVOcell technology into the marketplace and look forward to bringing greater resources to advance this effort. We anticipate this acquisition will serve as a platform to help accelerate building INVOcell’s presence in Canada.”
    • On September 7th,  INVO Bioscience announced that it has officially opened the Company’s 2nd INVO Center in the United States, based in Atlanta, Georgia after recently opening their first in Birmingham, AL called “Innovative Fertility Specialists, An INVO Center” on August 9th. INVO Centers are further scheduled this year to open in Monterrey, Mexico & the San Francisco Bay Area. This new joint-venture, named “Bloom Fertility, an INVO Center,” will focus on patients in need of advanced fertility care utilizing the efficient, effective, and affordable INVOcell solution. READ THE COMPLETE STORY. 

    • On August 16th, INVO announced their financial and operating results for the second quarter ended June 30, 2021 and provided a business update. Steve Shum , CEO of INVO stated. “Our team made excellent progress during the second quarter of 2021 toward our key objectives, headlined by last week’s official opening of our first INVO Center practice in Birmingham, AlabamaWe feel INVO is now well positioned for success based on the following core foundational elements developed over the past 2 years. We believe there is a substantial underserved patient population with infertility challenges and a real need to expand access to treatment. In our opinion, this is a multi-billion-dollar market expansion opportunity, and INVOcell is well positioned to address the unmet medical need.”
    • On Aug.2, INVO announced the Company’s first Joint Venture INVO Center practice in the United States, based in Birmingham, Alabama, was officially opening on August 9, 2021. Dr. Hammond commented, “With the opening of the country’s first INVOcell medical practice, we are advancing a core mission towards improving access to advanced fertility services for the many patients who would otherwise never have the opportunity. To date, we have already received numerous advanced inquiries via word of mouth and have dozens of patients scheduled for initial patient consultations who are eager to proceed with treatment. As we officially open the center next week, we expect to accelerate our marketing programs with the help of the INVO marketing team to enhance overall patient awareness around Innovative Fertility Specialists, An INVO Center.”
    • Over the past 40+ years, since the first IVF baby was born, the fertility market has grown into a $20+ billion global industry. Here in the U.S., according to the most recent 2019 CDC data, approximately 330,000 IVF cycles were performed across 448 clinics, which implies a roughly $5 billion domestic marketplace. However, this represents only a small portion of the actual market as approximately 90% of infertile couples go untreated each year. There are some real challenges with bridging the gap of treating the volume of patients that need care. Patient affordability and lack of insurance coverage is often the most discussed dynamic, but that is only one part of the challenge. We believe that there is an equal or even greater challenge related to capacity limitations in the industry given the relatively small number of IVF clinics and limited human resources available which are typically only available in major metropolitan areas. We believe that INVO Biosceince’s INVOcell, without the need of expensive lab build outs, can bring much needed capacity additions and access to the market beyond the major metropolitan areas at a more affordable price.


  • Shares of VP Watchlist firm, Seattle-based Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, closed at $3.50 , -11.84% on 11.74M shares of trading volume after reaching a high of $3.99 in intraday trading. 
    • On September 8th, Edward Woo, analyst at Ascendiant Capital Markets issued an update report titled “Q2 about inline. COVID-19 and breast cancer clinical trials expected to start soon should be catalysts for stock” and raided his P/T to $8.50.
    • On September 7th, Atossa adjourned its special stockholder meeting to 9:00 a.m. Eastern time on October 7, 2021 to allow additional time for stockholders to vote. The Company urges stockholders to vote on the proposal put forth in the proxy statement prior to the new meeting date. The purpose of the special meeting is to approve an increase in authorized shares of common stock, which requires the affirmative vote of a majority of the shares of common stock issued and outstanding as of the record date. While the votes cast to date have been strongly in favor of the proposal (73% of shares voted have been voted in favor), only 58% of the outstanding shares of common stock have been voted with 42% voting in favor of the proposal. Atossa is therefore adjourning the meeting for 30 days to allow additional time for stockholders to vote. Atossa stockholders may vote by calling (833) 786-6488 Monday through Friday 9 a.m. to 9 p.m. Eastern Time.
    • On Aug 13th, Atossa announced financial results for the fiscal quarter ended June 30, 2021, and provided an update on recent company developments. “We continue to experience encouraging progress in our MBD and COVID-19 programs, with new regulatory approvals being granted in Sweden for a Phase 2 trial in MBD and authorization in Australia to commence a Phase 2 study of AT-H201 for respiratory illness associated with COVID-19. In the meantime, we continue to enjoy a strong balance sheet, which we have significantly expanded over the last three quarters and will facilitate our development plans over the near term. As we actively explore the possibility for strategic expansion into other areas where we might see near-term milestones and results, we also urge all of our shareholders to exercise their right to vote at our special stockholder’s meeting on September 7, 2021. We urge a vote in favor of the proposal to increase authorized shares, which will provide the Company with the flexibility to issue shares as part of these potential acquisitions, collaborations and partnerships, a common strategy successful biotech companies seeking to grow shareholder value employ in order to create a more attractive opportunity for all. We look forward to continuing to update our stockholders on these opportunities as they develop,” stated Dr. Steven Quay, Atossa’s President and Chief Executive Officer.


  • Shares of VP Watchlist stock, InMed Pharmaceuticals, Inc. (NASDAQ: INM), a leading clinical-stage pharmaceutical company developing cannabinoid-based drug candidates for high unmet medical needs and IntegraSyn, a proprietary and cost effective manufacturing approach for synthesized rare cannabinoids, closed trading at $2.12, after reaching $2.05 during intraday trading.  The 52-wk range is $2.01 – $8.94. 
    • Today, September 13th, InMed announced that it has entered into a definitive agreement  to acquire BayMedica Inc., a private company based in the US that specializes in the manufacturing and commercialization of rare cannabinoids. The Definitive Agreement follows a previously signed letter of intent announced on June 29, 2021. The transaction, which is subject to certain standard closing conditions, is expected to close in the coming weeks. Upon closing, InMed will become a global leader in the manufacturing of rare cannabinoids, with expertise in three distinct and complementary cannabinoid manufacturing approaches. InMed’s proprietary cannabinoid manufacturing process, IntegraSyn™, combined with BayMedica’s synthetic biology and chemical synthesis capabilities, will provide InMed with complete manufacturing flexibility to select the most appropriate, cost-effective method based on the target cannabinoid and appropriate quality specifications for the desired market segment. In parallel to cannabinoid manufacturing, the combined company will continue to explore the therapeutic potential of cannabinoids and novel cannabinoid analogs for pharmaceutical drug development, as well as expand commercial sales of rare cannabinoids to the consumer health and wellness sector. Revenues of BayMedica’s initial rare cannabinoid product, Prodiol® CBC (cannabichromene), have grown steadily since sales commenced in December 2019, with cumulative revenues in excess of US$2.5M. BayMedica leads the industry in large batch production of CBC with current batch sizes of more than 200kg and an ability to increase to metric ton quantities as market demand increases. BayMedica is focused on the wholesale to consumer health and wellness markets, including nutraceuticals, cosmetic, functional food and beverage, as well as animal health markets. In addition to CBC, BayMedica has several high value non-intoxicating rare cannabinoids in various stages of commercial manufacturing scale-up including CBDV, THCV, CBGV, CBT and CBN for the health and wellness markets.

    • On July 9th, Roth Capital Partners analyst Scott Henry, CFA issued an update report with a BUY Rating titled, “INM: Favorable Take on BayMedica LOI” that includes a $11.50 12-Month Price target.
    • On Aug.9th, I published an informative story titled “A Recent Discussion With The CEO of InMed Pharmaceuticals (NASDAQ: INM) Regarding Development Of IntegraSyn™, A Proprietary Manufacturing Approach To Economically Produce Pharmaceutical-Grade Cannabinoids” PLEASE READ NOW.
    • On July 2nd, InMed announced that it had closed the previously announced private placement and after deducting the placement agent fees and estimated offering expenses payable by the Company, the Company received net proceeds of approximately US$11 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. Under the terms of the private placement, an aggregate of 4,036,327 common shares (or common share equivalents in lieu thereof) and warrants to purchase up to an aggregate of 4,036,327 common shares were purchased, at an effective purchase price of US$2.973 per common share (or common stock equivalent in lieu thereof) and associated warrant. The warrants have an exercise price of US$2.848 per share, are exercisable immediately and have a term of five years. InMed intends to use the net proceeds from the offering to continue pipeline development, advance business development activities and for general working capital purposes.
  •  

Economic Reports

  • On Monday, the macroeconomic schedule delivered the Treasury Budget report for August, which confirmed a $170.64B deficit in August, while the fiscal YTD budget deficit is $2.71T.

Investing & Inspiration

  1. “It takes a long time to grow an old friend.” – John Leonard
  2. “Life is a dream for the wise, a game for the fool, a comedy for the rich, a tragedy for the poor.”– Sholom Aleichem
  3. “The truth is you don’t know what is going to happen tomorrow. Life is a crazy ride, and nothing is guaranteed.” – Eminem
  4. “Man is only great when he acts from passion.” – Benjamin Disraeli
  5. “We need to stop thinking about infrastructure as an economic stimulant and start thinking about it as a strategy. Economic stimulants produce Bridges to Nowhere. Strategic investment in infrastructure produces a foundation for long-term growth.” – Roger McNamee
  6. “We must let go of the life we have planned, so as to accept the one that is waiting for us.” – Joseph Campbell
  7. “Put your heart, mind, and soul into even your smallest acts. This is the secret of success.” – Swami Sivananda
  8. “I can’t change the direction of the wind, but I can adjust my sails to always reach my destination.” – Jimmy Dean
  9. “Companies have too many experts who block innovation. True innovation really comes from perpendicular thinking.” – Peter Diamandis
  10. “By failing to prepare, you are preparing to fail.” – Benjamin Franklin
  11. “We cannot solve our problems with the same thinking we used when we created them.” – Albert Einstein
  12. “When you’re an investor, you can look at the quantitative and qualitative elements of an investment, but there’s a third aspect: What you feel in your gut.” – Kevin O’Leary
  13. “Set your course by the stars, not by the lights of every passing ship.” – Omar N. Bradley
  14. “Do not take life too seriously. You will never get out of it alive.” – Elbert Hubbard
  15. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey 
  16. “Every good painter paints what he is.” – Jackson Pollock
  17. “If you believe in yourself and have dedication and pride – and never quit, you’ll be a winner. The price of victory is high but so are the rewards.” – Bear Bryant
  18. “Your mindset matters. It affects everything – from the business and investment decisions you make, to the way you raise your children, to your stress levels and overall well-being.” – Peter Diamandis
  19. “You cannot have a positive life and a negative mind.” – Joyce Meyer 
  20. “Like wildebeest and zebra migration across the Serengeti, investment managers and consultants, too, have a habit of running together and, every now and then, changing direction.” – Sanjaya Baru
  21. “If people are anything but enthusiastic about the information or ideas that they’re sharing, they’re either not that invested in what they’re doing – or they’re not communicating that investment effectively.” – Ana Kasparian 
  22. “Life consists not in holding good cards but in playing those you hold well.” – Josh Billings 
  23. “Friend, there’s no greater investment in life than in being a people builder. Relationships are more important than our accomplishments.” – Joel Osteen
  24. “It’s only natural that the heavy users help contribute to the investment to keep the Web healthy. That is the most important concept of net neutrality.” – Lowell McAdam
  25. “The more sand that has escaped from the hourglass of our life, the clearer we should see through it.” – Jean Paul 
  26. “Eliminate emotion from your investment program.” -John C. Bogle

  27. “Modern medical advances have helped millions of people live longer, healthier lives. We owe these improvements to decades of investment in medical research.” – Ike Skelton
  28. “In every investment, before I get involved or invest, I always see what the mindset of the founder, the CEO, is.” – Zaza Pachulia
  29. “An investment said to have an 80% chance of success sounds far more attractive than one with a 20% chance of failure. The mind can’t easily recognize that they are the same.” – Daniel Kahneman
  30. “The return on investment in global health is tremendous, and the biggest bang for the buck comes from vaccines. Vaccines are among the most successful and cost-effective health investments in history.” – Seth Berkley
  31. “Few things in the world are more powerful than a positive push. A smile. A world of optimism and hope. A ‘you can do it’ when things are tough.” – Richard M. DeVos
  32. “To be yourself in a world that is constantly trying to make you something else is the greatest accomplishment.” – Ralph Waldo Emerson
  33. “We all have dreams. But in order to make dreams come into reality, it takes an awful lot of determination, dedication, self-discipline, and effort.”  – Jesse Owens
  34. “The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails.” – William Arthur Ward- American Writer, Born 1921
  35. “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
  36. “The secret of your future is hidden in your daily routine.” – Mike Murdock
  37.  “If somebody puts you down or criticizes you, just keep on believing in yourself and turn it into something positive.” – Leah LaBelle
  38. “Opportunity is missed by most people because it is dressed in overalls and looks like work”. -Thomas A. Edison
  39. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
  40. “Human behavior flows from three main sources: desire, emotion, and knowledge.” – Plato

  41. “We are what our thoughts have made us; so take care about what you think. Words are secondary. Thoughts live; they travel far.” – Swami Vivekananda
  42. “Success is not final, failure is not fatal: it is the courage to continue that counts.” – Winston Churchill
  43. “If you don’t know where you are going, any road will get you there.” – Lewis Carroll

  44. “Don’t worry about being a star, worry about doing good work, and all that will come to you.” – Ice Cube

  45. “It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare

  46. Prediction is very difficult, especially if it’s about the future.” – Niels Bohr (Danish Physicist)
  47. “It is indeed true that the stock market can forecast the business cycle.” -Paul Samuelson

  48. “The wisest rule in investment is: when others are selling, buy. When others are buying, sell. Usually, of course, we do the opposite. When everyone else is buying, we assume they know something we don’t, so we buy. Then people start selling, panic sets in, and we sell too.” – Jonathan Sacks

  49. “What lies behind you and what lies in front of you, pales in comparison to what lies inside of you.” – Ralph Waldo Emerson
  50. “Each new generation born is in effect an invasion of civilization by little barbarians, who must be civilized before it is too late.” – Thomas Sowell
  51. “Life is 10% what happens to you and 90% how you react to it.” – Charles R. Swindoll
  52. “The truth is you don’t know what is going to happen tomorrow. Life is a crazy ride, and nothing is guaranteed.” – Eminem
  53. “View health as an investment, not an expense.” – John Quelch

  54. “Opportunity does not knock, it presents itself when you beat down the door.” – Kyle Chandler

  55. “If you don’t know where you are going, any road will get you there.” – Lewis Carroll
  56. “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
  57. “That which does not kill us makes us stronger.” – Friedrich Nietzsche
  58. “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
  59. “A problem is a chance for you to do your best.”–  Duke Ellington
  60. “The best way to predict the future is to create it.” -Peter Drucker
  61. “I’m involved in the stock market, which is fun and, sometimes, very painful.” – Regis Philbin
  62. “Who owns the future? This is the question at the heart of every stock market.” – John Landgraf
  63. “One of the funny things about the stock market is that every time one person buys, another sells, and both think they are astute.” – William Feather
  64. While I’m sure some millennials are concerned with the ethical issues involved in mining for diamonds, the main reason they steer clear of the gems is because, well, they’re a dumb investment.” – Ana Kasparian
  65. “The wisest rule in investment is: when others are selling, buy. When others are buying, sell. Usually, of course, we do the opposite. When everyone else is buying, we assume they know something we don’t, so we buy. Then people start selling, panic sets in, and we sell too.” – Jonathan Sack
  66. “We must shift our thinking away from short-term gain toward long-term investment and sustainability, and always have the next generations in mind with every decision we make.” –  Deb Haaland
  67. “The only way to have a friend is to be one.” –  Ralph Waldo Emerson
  68. “If you believe in yourself and have dedication and pride – and never quit, you’ll be a winner. The price of victory is high but so are the rewards.” – Bear Bryant
  69. “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” -Liya Kebede

  70. “Success is not final, failure is not fatal: it is the courage to continue that counts.”– Winston Churchill
  71. “Our greatest glory is not in never falling, but in rising every time we fall.” – Confucius

  72. “Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes
  73. “Who controls the past controls the future. Who controls the present controls the past.” – George Orwell
  74. “If you get up in the morning and think the future is going to be better, it is a bright day. Otherwise, it’s not.” – Elon Musk
  75. “The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails.” – William Arthur Ward
  76. “Start where you are. Use what you have. Do what you can.” – Arthur Ashe
  77. “Netflix, Amazon, iTunes – whatever platforms emerge – we are looking at as having the same potential that home video had for the movie business. Which means there are entirely new opportunities to monetize our capital investment in content and do so in ways that work for distributors, for consumers and for creators.” – Bob Iger
  78. “When you have no one to answer to, vendetta as investment strategy is as legitimate as anything.” – Carl Icahn

  79. “No other investment yields as great a return as the investment in education. An educated workforce is the foundation of every community and the future of every economy.” – Brad Henry
  80. “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
  81. “Modern medical advances have helped millions of people live longer, healthier lives.

  82. We owe these improvements to decades of investment in medical research.”– Ike Skelton

  83. “Stock market goes up or down, and you can’t adjust your portfolio based on the whims of the market, so you have to have a strategy in a position and stay true to that strategy and not pay attention to noise that could surround any particular investment.” – John Paulson

  84. “Your mindset matters. It affects everything – from the business and investment decisions you make, to the way you raise your children, to your stress levels and overall well-being.” – Peter Diamandis
  85. “Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
  86. “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
  87. “I think you have to learn that there’s a company behind every stock and there’s only one real reason why stocks go up. Companies go from doing poorly to doing well or small companies grow to large companies.” – Peter Lynch
  88. “Historically, there has been a bull market in the commodities every 20 or 30 years.” – Jim Rogers
  89. “The markets generally are unpredictable, so that one has to have different scenarios. The idea that you can actually predict what’s going to happen contradicts my way of looking at the market.” – George Soros
  90. “Stop trying to predict the direction of the stock market, the economy or the elections.” – Warren Buffett
  91. “An important key to investing is to remember that stocks are not lottery tickets.” – Peter Lynch
  92. “Learn everyday, but especially from the experiences of others. It’s cheaper!” – John Bogle
  93. “When purchasing depressed stock in troubled companies, seek out the ones with the superior financial positions and avoid the ones with loads of bank debt.” – Peter Lynch
  94. “No stock price is too low for bears or too high for bulls.” – John F. Heerdink, Jr.
  95. “Investment is most successful when it is most businesslike.” – Ben Graham

  96. “Value stocks are about as exciting as watching grass grow, but have you ever noticed just how much your grass grows in a week?” – Christopher Browne

  97. “Even the intelligent investor is likely to need considerable willpower to keep from following the crowd.” – Benjamin Graham
  98. “Individual who cannot master their emotions are ill-suited to profit from the investment process.” – Benjamin Graham
  99. “I made my first investment at age eleven. I was wasting my life until then.” – Warren Buffet
  100. “I don’t look to jump over seven-foot bars; I look around for one-foot bars that I can step over.” — Warren Buffett
  101. “There are only three measurements that tell you nearly everything you need to know about your organization’s overall performance: employee engagement, customer satisfaction, and cash flow. It goes without saying that no company, small or large, can win over the long run without energized employees who believe in the mission and understand how to achieve it.” – Jack Welch, former CEO of GE
  102. “Opportunities come infrequently. When it rains gold, put out the bucket, not the thimble” ― Warren Buffett
  103. “If you buy things you do not need, soon you will have to sell things you need.” – Warren Buffet
  104. “How many millionaires do you know who have become wealthy by investing in savings accounts? I rest my case.” — Robert G. Allen
  105. “It’s far better to buy a wonderful company at a fair price, than a fair company at a wonderful price.” – Warren Buffett
  106. “A market downturn doesn’t bother us. It is an opportunity to increase our ownership of great companies with great management at good prices.” — Warren Buffett
  107. “Every once in a while, the market does something so stupid it takes your breath away.” — Jim Cramer
  108. “The person who starts simply with the idea of getting rich won’t succeed; you must have a larger ambition.” — John D. Rockefeller
  109. “Know what you own, and know why you own it.” – Peter Lynch
  110. “Although it’s easy to forget sometimes, a share is not a lottery ticket… it’s part ownership of a business.” – Peter Lynch
  111. “Wise spending is part of wise investing. And it’s never too late to start.” – Rhonda Katz
  112. “Invest for the long haul. Don’t get too greedy and don’t get too scared.” – Shelby M.C. Davis

  113. “Fear incites human action far more urgently than does the impressive weight of historical evidence.”
    -Jeremy Siegel
  114. “With a good perspective on history, we can have a better understanding of the past and present, and thus a clear vision of the future.” — Carlos Slim Helu
  115. “If we like a business, we’re going to buy as much of it as we can and keep it as long as we can. And when we change our mind, we don’t take half measures.” – Warren Buffett
  116. “The most contrarian thing of all is not to oppose the crowd but to think for yourself.” — Peter Thiel

  117. “Never depend on a single income, make an investment to create a second source.” Warren Buffet

  118. Games are won by players who focus on the playing field –- not by those whose eyes are glued to the scoreboard.”
    ― Warren Buffett
  119. “The key to making money in stocks is not to get scared out of them.” – Peter Lynch
  120. “Courage taught me no matter how bad a crisis gets … any sound investment will eventually pay off.” — Carlos Slim Helu
  121. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  122. “As time goes on, I get more and more convinced that the right method of investment is to put fairly large sums into enterprises which one thinks one knows something about and in the management of which one thoroughly believes.” — John Maynard Keynes
  123. “Given a 10% chance of a 100 times payoff, you should take that bet every time.” — Jeff Bezos
  124. “Money is always eager and ready to work for anyone who is ready to employ it.” ― Idowu Koyenikan
  125. The secret to investing is to figure out the value of something – and then pay a lot less.” – Joel Greenblatt
  126. “We don’t have an analytical advantage, we just look in the right place.” – Seth Klarman
  127. “Men, it has been well said, think in herds. It will be seen that they go mad in herds, while they only recover their senses slowly, and one by one.” – Charles Mackay
  128. “It’s not whether you’re right or wrong that’s important, but how much money you make when you’re right and how much you lose when you’re wrong.” – George Soros
  129. “No Price is too low for a bear or too high for a bull.” — Anonymous
  130. “Investment is an asset or item that is purchased with the hope that it will generate income or appreciate in the future.” Anonymous
  131. “Behind every stock is a company. Find out what it’s doing.” — Peter Lynch
  132. “Wise spending is part of wise investing. And it’s never too late to start.” –Rhonda Katz
  133. “It amazes me how people are often more willing to act based on little or no data than to use data that is a challenge to assemble.” ― Robert Shiller
  134. “A bull market is like sex. It feels best just before it ends.” — Barton Biggs
  135. “The investor’s chief problem — even his worst enemy — is likely to be himself.” — Benjamin Graham
  136. “No profession requires more hard work, intelligence, patience, and mental discipline than successful speculation.” – Robert Rhea
  137. “Money is like a sixth sense – and you can’t make use of the other five without it.” – William Somerset Maugham
  138. “Compound interest is the eighth wonder of the world. He who understands it, earns it. He who doesn’t, pays it.” — Albert Einstein
  139. “Never count on making a good sale. Have the purchase price be so attractive that even a mediocre sale gives good results” — Warren Buffett
  140. “The stock market is a device for transferring money from the impatient to the patient.” – Warren Buffett
  141. “Thousands of experts study overbought indicators, head-and-shoulder patterns, put-call ratios, the Fed’s policy on money supply…and they can’t predict markets with any useful consistency, any more than the gizzard squeezers could tell the Roman emperors when the Huns would attack.” – Peter Lynch
  142. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  143. “You cannot save time for your future use however you can invest time for your future.” – John F. Heerdink, Jr. 
  144. “Know what you own, and know why you own it.” – Peter Lynch
  145. “Liquidity is only there when you don’t need it.” -Old Proverb
  146. “If you want to be a millionaire, start with a billion dollars and launch a new airline.” – Richard Branson
  147. “Fear incites human action far more urgently than does the impressive weight of historical evidence.” – Jeremy Siegel
  148. “In investing, what is comfortable is rarely profitable.” – Robert Arnott
  149. “Spend each day trying to be a little wiser than you were when you woke up.” – Charlie Munger
  150. “The entrance strategy is actually more important than the exit strategy.” – Edward Lampert
  151. “The rivers don’t drink their own water; Trees don’t eat their own fruits. The sun does not shine for itself, And flowers do not spread their fragrance For themselves. Living for others is a rule of nature” – Pope Francis
  152. “It is impossible to produce superior performance unless you do something different from the majority.” – John Templeton
  153. “An investment in knowledge pays the best interest.” – Benjamin Franklin.
  154. I believe the returns on investment in the poor are just as exciting as successes achieved in the business arena, and they are even more meaningful!” -Bill Gates
  155. “Every portfolio benefits from bonds; they provide a cushion when the stock market hits a rough patch. But avoiding stocks completely could mean your investment won’t grow any faster than the rate of inflation.” – Suze Orman
  156. “The tax on capital gains directly affects investment decisions, the mobility, and flow of risk capital… the ease or difficulty experienced by new ventures in obtaining capital, and thereby the strength and potential for growth in the economy.” – John F. Kennedy
  157. “If all the economists were laid end to end, they’d never reach a conclusion. -George Bernard Shaw
  158. “There are old traders and there are bold traders, but there are very few old, bold traders.”-Ed Seykota
  159. “Let this scenario play out on its own, in its own fashion. As you watch it unfold, you will soon be grateful that you choose the peaceful path. Remember — those who live by the sword, die by the sword.”
  160. “As long as you enjoy investing, you’ll be willing to do the homework and stay in the game.” -Jim Cramer
  161. “I rarely think the market is right. I believe non-dividend stocks aren’t much more than baseball cards. They are worth what you can convince someone to pay for it.” -Mark Cuban
  162. Michael Marcus taught me one other thing that is absolutely critical: You have to be willing to make mistakes regularly; there is nothing wrong with it. Michael taught me about making your best judgment, being wrong, making your next best judgment, being wrong, making your third best judgment, and then doubling your money.” -Bruce Kovner
  163. “The policy of being too cautious is the greatest risk of all.” -Jawaharlal Nehru
  164. “The only true test of whether a stock is “cheap” or “high” is not its current price in relation to some former price, no matter how accustomed we may have become to that former price, but whether the company’s fundamentals are significantly more or less favorable than the current financial-community appraisal of that stock.” -Philip Fisher
  165. “I learned to avoid trying to catch up or double up to recoup losses. I also learned that a certain amount of loss will affect your judgment, so you have to put some time between that loss and the next trade.” -Richard Dennis
  166. “The four most dangerous words in investing are: ‘this time it’s different.” -Sir John Templeton
  167. “Money doesn’t make you happy. I now have $50 million but I was just as happy when I had $48 million.” -Arnold Schwarzenegger

Videos

Please consider viewing these interesting videos:



Post View Count : 501